2021-2022 Session
Change SessionS.22 (Act 61)
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
- Sponsor(s)
-
- Sen. Virginia Lyons
- Additional Sponsors
- Sen. Richard McCormack
- Last Recorded Action
- Senate 3/10/2021 - 3rd reading ordered
Bill/Resolution Text
NOTE: to print information that appears on a tab within the bill page, use the Print link on that tab.
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Detailed Status
Regular Session 2021-2022
| Body | Date | Journal | Calendar | Location | Full Status |
|---|
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Roll Call History
Regular Session 2021-2022
| Body | Date | Journal | Location | Full Status |
|---|
Although procedurally bills and resolutions are assigned to only one committee at a time, other committees may review the bill or resolution. This page contains results from both the assigned committee as well as other committees.
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Committee Meetings
Regular Session 2021-2022
| Meeting Date | Committee |
|---|
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Meeting Full List
Regular Session 2021-2022
Wednesday, January 27, 2021
- Committee(s):
- Senate Committee on Health and Welfare
- -
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Introduction, walk through
Sen. Virginia "Ginny" Lyons, Sponsor, Chittenden County
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Wednesday, February 10, 2021
- Committee(s):
- Senate Committee on Health and Welfare
- 11:00 AM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Walk-through, committee discussion
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Friday, February 19, 2021
- Committee(s):
- Senate Committee on Health and Welfare
- 9:00 AM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Testimony
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Cindy Bruzzese, Executive Director & Clinical Ethicist, Vermont Ethics Network
David Herlihy, Executive Director, Vermont Board of Medical Practice
Jill Abrams, Assistant Attorney General, Director, Consumer Protection Division, Attorney General's Office
Jessa Barnard, Executive Director, Vermont Medical Society
Tuesday, February 23, 2021
- Committee(s):
- Senate Committee on Health and Welfare
- 10:10 AM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Committee discussion
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Friday, February 26, 2021
- Committee(s):
- Senate Committee on Health and Welfare
- 9:30 AM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Committee discussion, vote
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Friday, March 19, 2021
- Committee(s):
- House Committee on Health Care
- 1:30 PM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Walk-through
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Wednesday, April 7, 2021
- Committee(s):
- House Committee on Health Care
- 10:00 AM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Sen. Cheryl Hooker, Reporter, Senate Health and Welfare
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
David Herlihy, Executive Director, Vermont Board of Medical Practice
Jessa Barnard, Executive Director, Vermont Medical Society
Cindy Bruzzese, Executive Director & Clinical Ethicist, Vermont Ethics Network
Jill Abrams, Assistant Attorney General, Director, Consumer Protection Division, Attorney General's Office
Wednesday, April 28, 2021
- Committee(s):
- House Committee on Health Care
- 9:00 AM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Committee discussion
Sam Russo, Vermont Association of Naturopathic Physicians
Lauren Hibbert, Director, Office of Professional Regulation, Secretary of State's Office
Friday, April 30, 2021
- Committee(s):
- House Committee on Health Care
- 10:50 AM
-
S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Vote
Committee Documents
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Witnesses Who Testified
Regular Session 2021-2022
House Committee on Health Care
- Jill Abrams, Assistant Attorney General, Director, Consumer Protection Division, Attorney General's Office
- Jessa Barnard, Executive Director, Vermont Medical Society
- Cindy Bruzzese, Executive Director & Clinical Ethicist, Vermont Ethics Network
- Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
- David Herlihy, Executive Director, Vermont Board of Medical Practice
- Lauren Hibbert, Director, Office of Professional Regulation, Secretary of State's Office
- Sen. Cheryl Hooker, Reporter, Senate Health and Welfare
- Sam Russo, Vermont Association of Naturopathic Physicians
- Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Senate Committee on Health and Welfare
- Jill Abrams, Assistant Attorney General, Director, Consumer Protection Division, Attorney General's Office
- Jessa Barnard, Executive Director, Vermont Medical Society
- Cindy Bruzzese, Executive Director & Clinical Ethicist, Vermont Ethics Network
- Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
- David Herlihy, Executive Director, Vermont Board of Medical Practice
- Sen. Virginia "Ginny" Lyons, Sponsor, Chittenden County
- Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Fiscal notes and materials available on this web page are provided for informational purposes only, and may not comprise all materials received by the Vermont Legislature or the final fiscal information related to a specific bill. The Legislature is not responsible for the accuracy of any information in these materials, and their posting does not constitute approval or endorsement by the Legislature.
No fiscal documents found for S.22 in the Regular Session 2021-2022.
No committee of conference members found for S.22 in the Regular Session 2021-2022.
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Committee of Conference Meetings
Regular Session 2021-2022
| Meeting Date | Committee |
|---|
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Committee of Conference Meeting Full List
Regular Session 2021-2022
No committee of conference meeting history found for S.22 in the Regular Session 2021-2022.
No committee of conference report found for S.22 in the Regular Session 2021-2022.
Act
An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration
Statutes Affected
Regular Session 2021-2022
| Statute |
|---|
| 3 V.S.A. § 129a. Unprofessional conduct |
| 18 V.S.A. §§ 4501-4507. Repealed. 1966, No. 53, eff. March 12, 1996. |
| 26 V.S.A. § 1354. Unprofessional conduct |
Staff & Other Information
- Staff
- Jennifer Carbee, Director and Chief Counsel
